Fourth Quarter & Full Year 2024 Results
Fourth quarter and full year 2024 results will be reviewed by management during a live audio webcast with the financial community on January 30, 2025. The presentation will be followed by a Q&A session.
Thursday January 30, 2025
15:00 - 16:30 CET (9:00am – 10:30am EST)
Featuring
Paul Hudson
Chief Executive Officer
François Roger
Chief Financial Officer
Houman Ashrafian
Head of Research and Development
Highlights
We exceeded expectations in 2024, achieving strong sales growth and significantly progressing our pipeline. Going forward, innovation will remain our key driver for launch excellence, as we become a fully focused, science-driven biopharma company.
Paul Hudson
Chief Executive Officer